We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
Impact BioMedical Inc.
Health Care · Biotechnology
Structural: microcap biopharma with four early-stage platforms spanning antivirals, antimicrobials, and consumer wellness - all pre-revenue or minimal revenue.
merger with Dr. Ashley's (July 2026 target) could inject commercial revenue and brand-name consumer distribution; 3F and Equivir platforms address persistent unmet need in broad-spectrum antimicrobials.
going-concern qualification, heavy cash burn, no meaningful product revenue, sub-$60M float with thin liquidity - execution and dilution risk are acute.
Each weekday: the scan's ENTER setups with entry, stop and target, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
No spam. One email per day max. Pro adds Telegram trade alerts and higher AI-assistant limits.
No major news in the last 7 days for IBO - only listicles and opinion pieces, which we filter out by default. See everything anyway.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.